Clik here to view.
Mallinckrodt touts data for Ofirmev injected acetaminophen
Mallinckrodt Pharmaceuticals (NYSE:MNK) today released results from a clinical pharmacokinetic study evaluating the effect of IV morphine on the absorption of oral acetaminophen, touting the...
View ArticleClik here to view.
Intarcia seeks FDA nod for Medici drug delivery system
Intarcia Therapeutics said today that it submitted a New Drug Application to the FDA for its injection-free ITCA 650 candidate, the 1st drug to use Intarcia’s Medici drug delivery system to treat Type...
View ArticleClik here to view.
GSK files for FDA approval of inhaled triple-combo therapy for COPD
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that GSK filed a regulatory submission with the FDA for the once-daily, closed triple combination therapy fluticasone...
View ArticleClik here to view.
Ivenix CEO Randle looks to reboot the infusion pump
Ivenix CEO Stuart Randle began his foray into drug pump delivery systems at Baxter in 1988, when he led the company’s effort to develop the 1st needle-free IV system. More than 20 years later, when he...
View ArticleClik here to view.
Mylan declines to testify at Senate committee hearing
Mylan (NDSQ:MYL) declined to testify at a U.S. Senate committee regarding its $465 million pending settlement to deal with charges that it underpaid government healthcare programs when it...
View ArticleClik here to view.
Topical immunotherapy combo effective against early skin cancer
Researchers from the Washington University School of Medicine and Harvard Medical School have shown that a combination of 2 topical drugs can trigger an immune response against precancerous skin...
View ArticleClik here to view.
Immunovaccine’s targeted ovarian cancer therapy wins orphan drug status in EU
Immunovaccine Inc. said today that the European Medicines Agency granted orphan drug designation for its immunotherapy candidate for ovarian cancer in the E.U. Orphan drug designation is granted to...
View ArticleClik here to view.
Allergan expands neurological portfolio with $125m Chase Pharmaceuticals buy
Allergan (NYSE:AGN) said today that it acquired Chase Pharmaceuticals for an upfront payment of $125 million, expanding the Dublin-based company’s neurological portfolio. Washington, D.C.-based Chase...
View ArticleClik here to view.
J&J approaches Actelion
Johnson & Johnson (NYSE:JNJ) is reportedly in preliminary discussions to buy Actelion Pharmaceuticals (VTX:ATLN) in a deal estimated to be as high as $247 (250 Swiss francs) per share, although the...
View ArticleClik here to view.
Researchers develop human lung model
(Reuters) – Czech scientists have developed a model of a functioning human lung that can be used to simulate problems like asthma or other chronic diseases and their treatments. The research group from...
View ArticleClik here to view.
Catalent to float $400m debt offering
Catalent (NYSE:CTLT) said today that it plans to fund its acquisition of soft-gel pharmaceutical capsule manufacturer Accucaps Industries Ltd with a $400 million debt offering. The Somerset, N.J.-based...
View ArticleClik here to view.
Intec Pharma inks deal with Michael J. Fox Foundation for patient recruitment
Intec Pharma (NSDQ:NTEC) said today that it inked a deal with the Michael J. Fox Foundation for Parkinson’s Research to support the biopharmaceutical company’s patient recruitment and retention for...
View ArticleClik here to view.
Engineered sugar clusters could enable targeted drug delivery
Researchers have developed a method to engineer sugar clusters attached to proteins or lipids, called glycan complexes, to target particular organs of the body. A team from the Riken Biofunctional...
View ArticleClik here to view.
Galera adds $15m for Series B
Galera Therapeutics said today that it landed $15 million for its severe oral mucositis treatment, bringing its Series B financing total to $57 million. Sofinnova Ventures led the round, joining...
View ArticleClik here to view.
Researchers develop bioresorbable capsule for treating hemophilia
Researchers from the Cockrell School of Engineering at the University of Texas at Austin have developed a biodegradable capsule to deliver a protein therapy for hemophilia. The research, published in...
View ArticleClik here to view.
Tests to begin for HIV therapy injections, long-acting implants
Drugs from companies such as GlaxoSmithKline (NYSE:GSK), Gilead Sciences (NSDQ:GILD) and Merck (NYSE:MRK) are reportedly being considered for large-scale trials evaluating injectable HIV prevention...
View ArticleClik here to view.
Windtree touts inhaled therapy for infants with respiratory distress syndrome
Windtree Therapeutics (NSDQ:WINT) today released data from a phase IIa trial evaluating its inhaled Aerosurf lucinactant designed for premature infants with respiratory distress syndrome. Results from...
View ArticleClik here to view.
Oramed touts phase Ib data for type 2 diabetes capsule
Oramed Pharmaceuticals (NSDQ:ORMP) said today that it finished a phase Ib study of its oral GLP-1 analog capsule for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) is a hormone that stimulates the...
View ArticleClik here to view.
Smart patch monitors blood, releases blood thinners to prevent clots
Researchers from the North Carolina State University and the University of North Carolina at Chapel Hill have developed a patch designed to monitor a patient’s blood and release blood-thinning drugs to...
View ArticleClik here to view.
Counterfeit prescription drug tracker raises $52m
TraceLink Inc. said yesterday that it raised $51.5 million in a Series C financing round, bringing its total raised to $77 million. The round was led by Goldman Sachs Growth Equity, joining FirstMark...
View Article